Nature of Disclosure: Regulatory intimation to stock exchanges regarding scheduled board meeting under SEBI LODR Regulation 29.
Board Meeting Details:
- Date: Monday, July 27, 2026
- Primary Agenda: Consider and approve the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026
- Additional Agenda: To transact other business matters
Trading Window Status:
- Trading window for dealing in securities remains closed from July 1, 2026
- Closure period: Until 48 hours after the Unaudited Consolidated and Standalone Financial Results for Q1 June 2026 are approved by the Board and submitted to Stock Exchanges
- Reference: Earlier intimation dated June 26, 2026
- Basis: Company's Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
Regulatory Compliance:
- Filed pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Addressed to Senior General Managers of Listing Departments at both BSE Limited and National Stock Exchange of India Limited
Company Information:
- Contact: P: +91 79 2999 9857 | E: info@senorespharma.com
- CIN No.: L24290GJ2017PLC100263
- Deval Rajnikant Shah, Whole-Time Director & CFO
- DIN: 00332722
- Digital signature with timestamp: July 21, 2026 at 15:55:48 +05'30'